Publicacións nas que colabora con Manuel Puig Domingo (26)

2024

  1. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2023

  1. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly

    Clinical Endocrinology, Vol. 99, Núm. 4, pp. 378-385

  2. Mortality in Acromegaly Diagnosed in Older Individuals in Spain Is Higher in Women Compared to the General Spanish Population

    The Journal of clinical endocrinology and metabolism, Vol. 108, Núm. 9, pp. 2193-2202

  3. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

2022

  1. Data mining analyses for precision medicine in acromegaly: a proof of concept

    Scientific Reports, Vol. 12, Núm. 1

  2. Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain

    Frontiers in Endocrinology, Vol. 13

  3. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas

    Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819

  2. Pasireotide in the Personalized Treatment of Acromegaly

    Frontiers in Endocrinology, Vol. 12

2020

  1. A consensus on the diagnosis and treatment of acromegaly comorbidities: An update

    Journal of Clinical Endocrinology and Metabolism, Vol. 105, Núm. 4, pp. E937-E946

  2. Molecular profiling for acromegaly treatment: a validation study

    Endocrine-related cancer, Vol. 27, Núm. 6, pp. 375-389

  3. Multidisciplinary management of acromegaly: A consensus

    Reviews in Endocrine and Metabolic Disorders, Vol. 21, Núm. 4, pp. 667-678

2019

  1. Strategic reflections of the Spanish Society of Endocrinology and Nutrition on the future of the speciality in the period 2018-2022

    Endocrinologia, Diabetes y Nutricion, Vol. 66, Núm. 10, pp. 654-662

2018

  1. Expert document on management of acromegaly

    Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 8, pp. 428-437

2017

  1. Prevención, diagnóstico y tratamiento de la obesidad. Posicionamiento de la Sociedad Española para el Estudio de la Obesidad de 2016

    Endocrinologia, Diabetes y Nutricion, Vol. 64, pp. 15-22

2016

  1. El Registro Molecular de Adenomas Hipofisarios (REMAH): una apuesta de futuro de la Endocrinología española por la medicina individualizada y la investigación traslacional

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 6, pp. 274-284

  2. Long-term treatment with pegvisomant for acromegaly: A 10-year experience

    Clinical Endocrinology, Vol. 84, Núm. 4, pp. 540-550

  3. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408

2015

  1. Hacia un manejo integral del paciente con diabetes y obesidad. Posicionamiento de la SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC

    Revista Clinica Espanola, Vol. 215, Núm. 9, pp. 505-514

2013

  1. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues

    European Journal of Endocrinology, Vol. 168, Núm. 1, pp. 9-13